Hyperphosphatemia Market is Projected to Grow During the Forecast Period 2032 – Estimates DelveInsight | Key Companies – Ardelyx, Kyowa Hakko Kirin, Shield Therapeutics, Chugai Pharmaceutical, Daiichi

 Breaking News
  • No posts were found

Hyperphosphatemia Market is Projected to Grow During the Forecast Period 2032 – Estimates DelveInsight | Key Companies – Ardelyx, Kyowa Hakko Kirin, Shield Therapeutics, Chugai Pharmaceutical, Daiichi

June 28
02:07 2022
Hyperphosphatemia Market is Projected to Grow During the Forecast Period 2032 - Estimates DelveInsight | Key Companies - Ardelyx, Kyowa Hakko Kirin, Shield Therapeutics, Chugai Pharmaceutical, Daiichi

DelveInsight’s Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hyperphosphatemia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).


Hyperphosphatemia: Overview

Hyperphosphatemia is a condition that is characterized by an increased level of phosphate in the blood. It is an asymptomatic effect/condition of another major underlying cause. The normal range for phosphorous is 2.5-4.5 mg/dL. Normal values may vary from laboratory to laboratory.


Explore more details of the market report- https://www.delveinsight.com/sample-request/hyperphosphatemia-market


Key highlights of the Hyperphosphatemia Market Report

  • As per the Centers for Disease Control and Prevention (2021), more than 1 in 7, i.e., 15% of US adults are estimated to have CKD and as many as 9 in 10 adults with CKD do not know they have CKD. CDC also mentioned that 2 in 5 adults with severe CKD do not know they have CKD.
  • More than 661,000 Americans have kidney failure. Of these, 468,000 individuals are on dialysis, and roughly 193,000 live with a functioning kidney transplant (National Institute of Diabetes and Digestive and Kidney Diseases, n.d).
  • As CKD progresses, modest increases in serum phosphate levels within the normal range increase the filtered load of phosphate, and at the same time, the fractional excretion of filtered phosphate increases from 10% to >50%. Only after these compensations are exhausted does overt hyperphosphatemia occur, typically in CKD stages 4-5.


Hyperphosphatmia Epidemiology Insights

Hyperphosphatemia is common in the late stages of chronic kidney disease and is often associated with elevated parathormone levels, abnormal bone mineralization, extra-osseous calcification, and increased risk of cardiovascular events and death. Several classes of oral phosphate binders are available to help control plasma phosphorus levels. Although effective at lowering serum phosphorus, they all have safety, tolerability, and compliance issues that need to be considered when selecting which one to use.


Hyperphosphatmia Epidemiology Segmentation in the 7MM

  • Total Prevalent Cases
  • Total Symptomatic and asymptomatic Prevalent Cases
  • Total Diagnosed Prevalent Cases
  • Treated Cases


Hyperphosphatemia Market

Hyperphosphatemia market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Hyperphosphatemia in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period. The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hyperphosphatmia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.


Hyperphosphatemia Market Insights

Excess phosphorus levels in ESRD have been linked to a rise in the risk of cardiovascular disease, as well as rises in serum Fibroblast growth factor 23 (FGF-23), a significant serum endocrine hormone that controls phosphorus metabolism, and elevated parathyroid hormone, also known as secondary hyperparathyroidism. Since dialysis is not efficient at removing excess phosphorus, the mainstay of treatment in patients with hyperphosphatemia in advanced chronic kidney disease is the reduction of phosphate intake, which is usually accomplished with avoidance of foods containing high amounts of phosphate and with the use of phosphate-binding drugs taken with meals. Although quite effective, aluminum-containing antacids should not be used as phosphate-binding agents in patients with end-stage renal disease because of the possibility of aluminum-related dementia and osteomalacia (a condition where bones become soft and weak).


Hyperphosphatmia Treatment Market

In September 2014, Auryxia (ferric citrate) was approved by the US FDA for the control of serum phosphorus levels in adults with CKD on dialysis. Apart from this, branded and generic version Sevelamer is available in the market, to control phosphorus levels in adults and children. Fosrenol is a phosphate binder that is indicated for use in ESRD (stage 5) receiving dialysis and, from October 2009, is also indicated in the EU for the treatment of adult patients with CKD who are not on dialysis with serum phosphate > 1.78 mmol/L (5.5 mg/dL) in which a low phosphate diet alone is insufficient to control serum phosphate levels.


Hyperphosphatmia Market Dynamics

The dynamics of the Hyperphosphatemia market is anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this indication. Key players, such as Ardelyx/Kyowa Hakko Kirin, Shield Therapeutics, Chugai Pharmaceutical, Daiichi Sankyo and others are involved in developing novel therapies for Hyperphosphathemia which will eventually influence the market size during the forecast period [2021–2030].


Hyperphosphatmia Market Companies includes-

  • Akebia Therapeutics
  • Vifor Fresenius Medical Care Renal Pharma
  • Astellas Pharma
  • Ardelyx
  • Shield Therapeutics, and several others


Hyperphosphatmia Market Drugs includes-

  • Auryxia (ferric citrate)
  • Tenapanor
  • PT-20, and several others


Hyperphosphatmia Market Drivers

  • Expected rise in cases of chronic kidney disease and patients progressing towards end stage renal disease
  • Emerging assets targeting underlying cause of Hyperphosphatemia with strong safety profile and reducing pill burden


Hyperphosphatmia Market Barriers

  • Frequent dosing pattern of phosphate binders
  • Safety and tolerability concerns of approved therapies


Explore more information on the market report- https://www.delveinsight.com/sample-request/hyperphosphatemia-market


Table of Content

1. Key Insights

2. Executive Summary of Hyperphosphatemia

3. Competitive Intelligence Analysis for Hyperphosphatemia

4. Hyperphosphatemia: Market Overview at a Glance

5. Hyperphosphatemia: Disease Background and Overview

6. Patient Journey

7. Hyperphosphatemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperphosphatemia Unmet Needs

10. Key Endpoints of Hyperphosphatemia Treatment

11. Hyperphosphatemia Marketed Products

12. Hyperphosphatemia Emerging Therapies

13. Hyperphosphatemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Hyperphosphatemia Market Outlook

16. Access and Reimbursement Overview of Hyperphosphatemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/